Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Pipeline Review, H1 2017

  • ID: 4311880
  • Drug Pipelines
  • 26 pages
  • Global Markets Direct
1 of 5
Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Pipeline Review, H1 2017

Summary:

Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Mitogen-activated protein kinase 9 is an enzyme that is encoded by the MAPK9 gene. This kinase targets specific transcription factors and thus mediates immediate-early gene expression in response to various cell stimuli. This kinase blocks the ubiquitination of tumor suppressor p53, and thus increases the stability of p53 in nonstressed cells.

Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical stages are 4 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Oncology which include indications Parkinson's Disease, Atherosclerosis, Breast Cancer and Multiple Sclerosis.

The latest report Mitogen Activated Protein Kinase 9 - Pipeline Review, H1 2017, outlays comprehensive information on the Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24)
  • The report reviews Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
  1. Introduction
  2. Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Overview
  3. Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Companies Involved in Therapeutics Development
  14. Eisai Co Ltd
  15. OPKO Health Inc
  16. Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Drug Profiles
  17. ER-358063 - Drug Profile
  18. Product Description
  19. Mechanism Of Action
  20. R&D Progress
  21. Small Molecules to Activate JNK-1, JNK-2 and p38 MAP Kinase for Breast Cancer - Drug Profile
  22. Product Description
  23. Mechanism Of Action
  24. R&D Progress
  25. Small Molecules to Inhibit JNK1, JNK2 and JNK3 for Parkinson’s Disease - Drug Profile
  26. Product Description
  27. Mechanism Of Action
  28. R&D Progress
  29. SR-3306 - Drug Profile
  30. Product Description
  31. Mechanism Of Action
  32. R&D Progress
  33. TT-301 - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Dormant Products
  38. Appendix
  39. Methodology
  40. Coverage
  41. Secondary Research
  42. Primary Research
  43. Expert Panel Validation
  44. Contact Us
  45. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indication, H1
  4. Number of Products under Development by Companies, H1
  5. Products under Development by Companies, H1
  6. Number of Products under Investigation by Universities/Institutes, H1
  7. Products under Investigation by Universities/Institutes, H1
  8. Number of Products by Stage and Mechanism of Actions, H1
  9. Number of Products by Stage and Route of Administration, H1
  10. Number of Products by Stage and Molecule Type, H1
  11. Pipeline by Eisai Co Ltd, H1
  12. Pipeline by OPKO Health Inc, H1
  13. Dormant Projects, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products by Mechanism of Actions, H1
  5. Number of Products by Stage and Mechanism of Actions, H1
  6. Number of Products by Molecule Types, H1
  7. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Eisai Co Ltd
  • OPKO Health Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll